Table 3:

Subgroup Analyses of Time Spent in Glucose Range and Hypoglycemia Among People with Type 1 Diabetes who Use Multiple Daily Injections

Group Mean				Difference Between Flash and SMBG (% Change)	Difference in Adjusted Means Between Flash and SMBG (95% CI)	P Value
Flash		SMBG
Baseline	Study End	Baseline	Study End
Hours in target glucose range (3.9–10.0 mmol/L) within 24 hours
15.0	15.7	14.3	14.3	6.5%	0.9 (0.2 to 1.7)	.011
Hours in hypoglycemia (< 3.9 mmol/L) within 24 hours
3.44	1.86	3.73	3.66	−46.0%	−1.65 (−2.21 to −1.09)	< .0001
Hours in hypoglycemia at night (11 pm-6 am) within 7 hours
1.20	0.61	1.41	1.28	−46.6%	−0.57 (−0.81 to −0.34)	< .0001
Mean hypoglycemia events < 3.9 mmol/L (70 mg/dL) within 24 hours
1.80	1.23	1.72	1.78	−32.8%	−0.59 (−0.78 to −0.40)	< .0001
Hours above target glucose range (> 13.3 mmol/L) within 24 hours
1.77	1.78	2.05	2.10	−9.2%	−0.19 (−0.58 to 0.21)	.36
Mean amplitude of glucose excursiona
7.9	7.5	8.2	8.0	−3.9%	−0.31 (−0.72 to 0.11)	.14
Blood glucose risk indexa
8.1	7.4	8.7	8.6	−9.4%	−0.8 (−1.4 to −0.1)	.017
Coefficient of variation in glucose, %a
43.2	37.8	43.4	42.6	−11.1%	−4.7 (−6.2 to −3.2)	< .0001
Low blood glucose risk indexa
2.70	1.61	2.87	2.77	−39.3%	−1.07 (−1.42 to −0.72)	< .0001
Standard deviation of glucose, (mmol/L)a
3.36	3.10	3.41	3.36	−6.9%	−0.23 (−0.39 to −0.07)	.0051
Continuous overlapping net glycemic action, 2 hours, mg/dLa
3.2	2.8	3.2	3.3	−14.8%	−0.48 (−0.66 to −0.30)	< .0001
Continuous overlapping net glycemic action, 6 hours, mg/dLa
4.0	3.7	4.0	4.1	−9.7%	−0.39 (−0.85 to 0.06)	.089

Abbreviations: CI, confidence interval; SMBG, self-monitoring of blood glucose.

^aA scale for measuring glucose variability

Source: Oskarsson et al.⁴⁹